Cannabis Hyperemesis Syndrome is a real but poorly recognized condition in young chronic cannabis users, marked by cyclic vomiting and compulsive hot bathing. A 2025 narrative review organizes the scattered evidence into a useful clinical framework, though the underlying data remain extremely limited, consisting mostly of individual case reports and small case series.

Cannabis use among young people is rising globally, and THC potency has increased substantially over the past two decades. Cannabis Hyperemesis Syndrome remains chronically underdiagnosed, often leading to repeated emergency department visits, unnecessary invasive workups, and prolonged patient suffering. Clinicians who care for adolescents and young adults need practical awareness of this condition now, even as the research community works to build a stronger evidence foundation. The stakes are especially high because the only consistently effective treatment, cannabis cessation, requires early recognition that the condition exists.

Cannabis Hyperemesis Syndrome is a condition first described in 2004, characterized by recurrent episodes of severe nausea, cyclic vomiting, and diffuse abdominal pain in the setting of chronic cannabis use. The condition progresses through three recognized phases: a prodromal stage of early morning nausea often paradoxically treated with more cannabis, a hyperemetic phase of intense vomiting with risk of dehydration and electrolyte derangement, and a recovery phase that follows cannabis cessation. A hallmark behavioral feature is compulsive hot bathing, which provides temporary symptomatic relief through mechanisms thought to involve TRPV1 receptor activation and redirection of blood flow. The proposed pathophysiology centers on cannabinoid receptor dysregulation and disruption of gut motility signaling, though mechanistic details remain poorly understood.

This 2025 narrative review by Seabrook and colleagues synthesizes 13 original research articles spanning 2004 to 2024, including six case reports, three case series, one randomized controlled trial of 33 subjects, and one population-level study from Ontario that examined 12,866 emergency department visits. The Ontario study found a 1.49-fold increase in CHS-related ED visits following cannabis commercialization, particularly among women and individuals aged 19 to 24, though this increase was concurrent with the COVID-19 pandemic and cannot be attributed to commercialization alone. The sole RCT found haloperidol outperformed ondansetron for acute symptoms, though it involved only 33 patients and two cases of acute dystonia occurred. The authors acknowledge that the youth-specific evidence is extremely thin and call for prospective cohort studies, validated diagnostic criteria, and larger treatment trials.

Cannabis Hyperemesis Syndrome in Youth: Real Condition, Thin Evidence, and What Clinicians Need to Know

A teenager comes to the emergency department for the third time in six months with severe vomiting that only stops when she stands under scalding hot water for hours. She uses cannabis daily. Most clinicians will miss the diagnosis, not because they lack intelligence, but because Cannabis Hyperemesis Syndrome is still largely invisible in medical education. This 2025 review by Seabrook and colleagues attempts to change that, and in its core clinical mission it succeeds. The three-phase model of CHS, the hot-bathing hallmark, and the cessation imperative are all presented with clarity and practical intent. These are genuinely useful contributions. Any clinician who has puzzled over a young patient with unexplained cyclic vomiting and a cannabis use history will find a recognizable clinical framework here. The review also correctly identifies that rising THC potency and expanding legal markets create a convergent risk environment that makes clinical awareness more urgent with each passing year. What the review contributes before any critique is straightforward: it makes a scattered, difficult-to-access body of literature navigable for the first clinician encountering this problem.

Where I grow more cautious is in the distance between what this review can actually demonstrate and what it sometimes implies. The total patient-level evidence base for CHS in youth is strikingly small. The most comprehensive youth-specific systematic review cited, by Zhu and colleagues, covered just 24 patients across 21 studies. Most of the included articles are individual case reports. The single randomized controlled trial involved only 33 subjects and addressed a narrow pharmacological question. To put this in proportion: recommending citywide traffic redesign based on a handful of accident reports, before any systematic traffic study has been conducted, would strike us as premature even if the accidents were real and alarming. The accidents are real here too. CHS genuinely causes suffering, and I have seen it in my own practice. But the leap from case report awareness to public health policy mandates, including school-based prevention programs and implications about cannabis commercialization as a driver of CHS, outpaces the evidentiary foundation. The Ontario study that found a 1.49-fold increase in CHS-related emergency visits after commercialization is observational and confounded by the concurrent arrival of COVID-19. Concluding that a new restaurant caused food poisoning when it opened during a norovirus outbreak is tempting but analytically insufficient. The review’s advocacy framing is understandable given the urgency of the topic, but it risks being mistaken for established causal fact by readers who do not parse methodological nuance.

What would I say in practice? To a patient: if you use cannabis regularly and experience episodes of severe nausea and vomiting that only improve in a hot shower, we need to have a serious conversation, because this pattern strongly suggests CHS, and stopping cannabis is the only thing that reliably resolves it. To a colleague: ask about hot bathing behavior, take a thorough cannabis use history, and know that cessation is definitive treatment while haloperidol and topical capsaicin may help acutely. To a policymaker: we have enough evidence to justify including CHS in clinician education and cannabis product health warnings, but not enough to quantify the population burden or to know which specific interventions will reduce it. Invest in the research infrastructure before mandating programs we cannot yet evaluate. When a condition is underrecognized and the evidence base is thin, narrative reviews serve a valuable awareness function, but awareness documents should be clearly labeled as such and not mistaken for clinical guidelines. The urgency of the problem does not upgrade the quality of the evidence.

This review sits very early in the research arc for CHS in youth. The condition was first described two decades ago, yet the total accumulated evidence in adolescents and young adults could be summarized in a few pages. Most of what we know derives from adult populations, and the extrapolation to youth is reasonable but unvalidated. The study serves best as a consciousness-raising document for clinicians in emergency medicine, primary care, and adolescent health who may encounter CHS without recognizing it, and for researchers who need a clear map of the gaps requiring investigation.

From a pharmacological standpoint, clinicians should note that haloperidol showed promise in the single small RCT but carries the risk of acute dystonia, particularly at higher doses, which is an important safety consideration in young patients. Topical capsaicin appears to offer symptomatic relief based on a 13-patient case series, but dosing protocols and safety data in adolescents are not established. Standard antiemetics such as ondansetron were not reliably effective in the adolescent case series. For practicing clinicians, the most concrete and immediately actionable recommendation is this: in any young patient presenting with recurrent unexplained vomiting, ask about cannabis use patterns and hot bathing behavior, because recognizing the pattern early can prevent months of unnecessary diagnostic workup and suffering.

This is a narrative review, not a systematic review or meta-analysis, despite using a modified PRISMA flow diagram to document its literature search. It synthesizes 13 primary studies identified through PubMed and Google Scholar without formal risk-of-bias assessment, pre-registered protocol, or pooled effect estimation. Its position in the evidence hierarchy is low, and the single most important inference constraint is that narrative reviews are inherently susceptible to selection bias and author framing, meaning the completeness and objectivity of the synthesis cannot be independently verified.

This review largely confirms and organizes findings that have accumulated since Allen and colleagues first described CHS in 2004. The three-phase clinical model and the centrality of cannabis cessation as treatment are consistent across the broader literature. The Ontario population-level data from Myran et al. (2022) add epidemiological context that was previously absent, suggesting a quantifiable increase in CHS-related emergency department utilization tied to cannabis commercialization, though with important confounders. What this review adds specifically is a youth-focused lens, drawing on the Zhu et al. (2021) systematic review of 24 adolescent patients and the Lonsdale et al. (2021) case series of 34 adolescents, both of which remain among the only youth-specific datasets available. The review does not challenge prior findings so much as it reveals how little youth-specific evidence exists to either confirm or complicate the adult-derived clinical model.

The most consequential analytic choice was the decision to conduct a narrative rather than a systematic review. A formally systematic approach with pre-registered protocol, expanded database coverage beyond PubMed and Google Scholar, and structured quality appraisal of each included study would have produced a more defensible synthesis. It might also have identified additional relevant studies or revealed systematic patterns in study quality that would temper or strengthen specific conclusions. The absence of formal risk-of-bias assessment means that readers cannot distinguish between well-designed case series and poorly documented case reports in the review’s synthesis, which may lead to overweighting of weaker evidence. A systematic approach would not have overcome the fundamental limitation of small sample sizes, but it would have made the boundaries of the evidence more transparent.

The most likely overinterpretation is reading the Ontario emergency department data as proof that cannabis legalization or commercialization causes CHS in young people. The Ontario study by Myran et al. found no immediate or gradual change attributable to legalization itself; the increase was specifically tied to the commercialization period, which overlapped with the COVID-19 pandemic. These confounders cannot be separated in the available data. Similarly, readers may treat the review’s three-phase clinical model as empirically validated in youth specifically, when in reality it derives primarily from adult case series and has only limited youth-specific support. The review’s authoritative clinical narrative and public health framing may inadvertently lead non-specialist readers to mistake expert synthesis and opinion for the strength of established clinical guidelines.

This review contributes a useful, clinically organized synthesis of an underrecognized condition in a vulnerable population. It does not establish validated prevalence estimates, causal relationships between cannabis policies and CHS, or evidence-based treatment protocols beyond cannabis cessation. For practice now, the hot-bathing hallmark is a genuinely valuable diagnostic clue, cessation counseling is the cornerstone of management, and clinicians should maintain a high index of suspicion in young patients with recurrent unexplained vomiting and chronic cannabis use.

What is Cannabis Hyperemesis Syndrome?

CHS is a condition that can develop in people who use cannabis frequently over a long period of time. It causes repeated episodes of severe nausea, vomiting, and abdominal pain. A distinctive feature is that sufferers often find temporary relief only through prolonged hot showers or baths. The condition resolves when cannabis use is stopped completely.

How common is CHS in young people?

Reliable prevalence data do not yet exist for CHS in youth. The condition is widely considered underdiagnosed because many clinicians are unfamiliar with it. Population-level data from Ontario suggest that emergency department visits related to CHS have increased, particularly among young adults aged 19 to 24, but the true frequency of the condition in young cannabis users remains unknown.

Is there any treatment besides stopping cannabis?

Cannabis cessation is the only treatment that consistently and durably resolves CHS. For acute symptom management in the emergency setting, haloperidol and topical capsaicin cream have shown some promise in very small studies, but standard anti-nausea medications like ondansetron have not been reliably effective. Any pharmacological treatment should be discussed with a physician who is familiar with the condition.

Does higher THC potency make CHS more likely?

This is a plausible hypothesis supported by the observation that THC concentrations in cannabis products have roughly doubled over the past decade, and CHS reports appear to be increasing. However, a direct causal link between THC potency and CHS risk has not been established in controlled studies. More research is needed to determine whether potency is an independent risk factor or whether it correlates with other aspects of heavy use.

Have thoughts on this? Share it: